BioCentury | Apr 14, 2020
Product Development

COVID-19 roundup: Can-Fite repurposing RA therapy; plus Brazilian chloroquine study points to cardiotoxicity, Athersys stem cell trial, Rutgers saliva test

As Can-Fite begins testing the first ADORA3 agonist against COVID-19, the latest red flag for chloroquine came with the immediate termination of the high dose arm of a Brazilian trial of the repurposed malaria drug....
BioCentury | Jan 7, 2020
Finance

BioIntervene takes on adenosine in pain, raises $30M

With IP from St. Louis University and NIH, BioIntervene raised a $30 million series A round from MPM Capital to bring what could be a first-in-class pain therapy into the clinic. The company plans to...
BC Innovations | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
BC Week In Review | Aug 10, 2018
Company News

China Medical gains rights to Can-Fite's ADORA3 agonists

CMS Medical Venture Investment Ltd. gained rights to develop and commercialize piclidenoson (CF101) and namodenoson (CF102) in Taiwan and China, including Hong Kong and Macau, from Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-A:CANF). Can-Fite received $2...
BC Week In Review | Jan 20, 2017
Financial News

Can-Fite completes direct public offering

Cancer and inflammatory disease company Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF) raised $5 million through the sale of 2.5 million ADSs at $2 in a registered direct offering with institutional investors on Jan. 19. Investors...
BC Week In Review | Jul 18, 2016
Clinical News

Piclidenoson: Phase II data

Top-line data from a double-blind, international Phase II trial in 89 patients with ocular hypertension and/or glaucoma showed that twice-daily oral CF101 missed the primary endpoint of reducing IOP from baseline to week 16 vs....
BC Week In Review | Oct 19, 2015
Financial News

Can-Fite completes direct public offering

Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF), Petah Tikva, Israel   Business: Cancer, Infectious, Autoimmune   Date completed: 2015-10-13   Type: Direct public offering   Raised: $4.8 million   Shares: 1.1 million   Price: $4.35  ...
BC Week In Review | Sep 28, 2015
Financial News

Can-Fite completes direct public offering

Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF), Petah Tikva, Israel   Business: Cancer, Infectious, Autoimmune   Date completed: 2015-09-21   Type: Direct public offering   Raised: $9 million   Shares: 2.1 million   Price: $4.35  ...
BC Week In Review | Sep 21, 2015
Clinical News

CF102 regulatory update

FDA granted Fast Track designation to Can-Fite’s CF102 as a second-line treatment for hepatocellular carcinoma (HCC). The nucleoside adenosine A3 receptor (ADORA3) agonist is in Phase II testing to treat HCC and has Orphan Drug...
BC Week In Review | May 11, 2015
Clinical News

IB-MECA: Additional Phase II/III data

Additional data from a double-blind, international Phase II/III trial in 326 patients with moderate to severe plaque psoriasis showed that twice-daily oral CF101 led to a 57% mean improvement in PASI score from baseline to...
Items per page:
1 - 10 of 116
BioCentury | Apr 14, 2020
Product Development

COVID-19 roundup: Can-Fite repurposing RA therapy; plus Brazilian chloroquine study points to cardiotoxicity, Athersys stem cell trial, Rutgers saliva test

As Can-Fite begins testing the first ADORA3 agonist against COVID-19, the latest red flag for chloroquine came with the immediate termination of the high dose arm of a Brazilian trial of the repurposed malaria drug....
BioCentury | Jan 7, 2020
Finance

BioIntervene takes on adenosine in pain, raises $30M

With IP from St. Louis University and NIH, BioIntervene raised a $30 million series A round from MPM Capital to bring what could be a first-in-class pain therapy into the clinic. The company plans to...
BC Innovations | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
BC Week In Review | Aug 10, 2018
Company News

China Medical gains rights to Can-Fite's ADORA3 agonists

CMS Medical Venture Investment Ltd. gained rights to develop and commercialize piclidenoson (CF101) and namodenoson (CF102) in Taiwan and China, including Hong Kong and Macau, from Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-A:CANF). Can-Fite received $2...
BC Week In Review | Jan 20, 2017
Financial News

Can-Fite completes direct public offering

Cancer and inflammatory disease company Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF) raised $5 million through the sale of 2.5 million ADSs at $2 in a registered direct offering with institutional investors on Jan. 19. Investors...
BC Week In Review | Jul 18, 2016
Clinical News

Piclidenoson: Phase II data

Top-line data from a double-blind, international Phase II trial in 89 patients with ocular hypertension and/or glaucoma showed that twice-daily oral CF101 missed the primary endpoint of reducing IOP from baseline to week 16 vs....
BC Week In Review | Oct 19, 2015
Financial News

Can-Fite completes direct public offering

Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF), Petah Tikva, Israel   Business: Cancer, Infectious, Autoimmune   Date completed: 2015-10-13   Type: Direct public offering   Raised: $4.8 million   Shares: 1.1 million   Price: $4.35  ...
BC Week In Review | Sep 28, 2015
Financial News

Can-Fite completes direct public offering

Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF), Petah Tikva, Israel   Business: Cancer, Infectious, Autoimmune   Date completed: 2015-09-21   Type: Direct public offering   Raised: $9 million   Shares: 2.1 million   Price: $4.35  ...
BC Week In Review | Sep 21, 2015
Clinical News

CF102 regulatory update

FDA granted Fast Track designation to Can-Fite’s CF102 as a second-line treatment for hepatocellular carcinoma (HCC). The nucleoside adenosine A3 receptor (ADORA3) agonist is in Phase II testing to treat HCC and has Orphan Drug...
BC Week In Review | May 11, 2015
Clinical News

IB-MECA: Additional Phase II/III data

Additional data from a double-blind, international Phase II/III trial in 326 patients with moderate to severe plaque psoriasis showed that twice-daily oral CF101 led to a 57% mean improvement in PASI score from baseline to...
Items per page:
1 - 10 of 116